Site icon BottomFishing India

Top Ten Covid Performers: Best Pharma Shares Apr-Jun 2020

index stocks at 52-week

Top Ten Covid Performers: Best Nifty Pharma Index Shares Apr to Jun 2020

After the onset of Covid-19 virus pandemic in India during early March this year and subsequent imposition of lockdown measures in India and across the globe severely impacted capital market in India. Capital market also bore the brunt of flight of capital during this period as global markets went on a tailspin. The top ten Covid performers in Pharma sector comprise of various sizes from large scale to medium and small listed companies on various Nifty indices. Top ten is dominated by Nifty250 pharma companies followed Nifty100 companies. Cipla (NSE: CIPLA) is the only major pharma company to feature in the list.

Source: NSE

Glenmark Pharmaceuticals (NSE: GLENMARK) and Syngene International (NSE: SYNGENE) were the topmost consistent price return performers during this period. Both of these stocks gave positive price return on 10 out of 13 weeks and were negative for remaining three weeks. Alembic Pharmaceuticals (NSE: APLLTD), Cadila Healthcare (NSE:CADILAHC) and FDC Ltd (NSE:FDC) were the other stocks in top five most consistent price return stocks during this period.

Jubilant Life Sciences (NSE: JUBILANT) has given highest price returns during this period followed by   Glenmark Pharmaceuticals (NSE: GLENMARK). JUBILANT stock price rose by 147% during this period, while GLENMARK share price rose by 129%. JUBILANT was not only the most consistent price return pharma stock but also give one of the highest price returns.

Remaining eight of the top ten stocks has delivered less than 100% price gains during this period.  Cadila Healthcare (NSE:CADILAHC) despite be consistent weekly positive price momentum has delivered second lowest price gains during this period, it grew by only 38%. J B Chemicals and Pharmaceuticals (NSE: JBCHEPHARM) delivered only 34% price returns during entire period despite remaining positive on eight weeks of price momentum.

Exit mobile version